Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome

A Short Term Outcomes of Subacromial Injection of Combined Corticosteroid With Low Volume Compared to High Volume of Local Anesthetic for Rotator Cuff Impingement Syndrome: A Randomized Controlled Trials

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03120923

Enrollment

Registered

2017-04-19

Start date

2015-01-01

Completion date

2016-08-01

Last updated

2017-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impingement Shoulder

Keywords

subacromial injection

Brief summary

This study aims to assess and compare the effectiveness of two different volumes of local anesthetic combined with 40mg of triamcinolone for subacromial injections in treating patients with rotator cuff impingement syndrome

Detailed description

Patients with rotator cuff impingement syndrome were randomized to undergo subacromial injection with 10mL total volume of 1% lidocaine plus 40mg triamcinolone acetonide (n = 22), or a 4mL total volume of 1% lidocaine plus 40-mg triamcinolone acetonide (n = 23). Evaluations using a visual analog scale (VAS) for pain during motion, and the Western Ontario Rotator Cuff Index (WORC) were completed before treatment and 30 minutes, 2 weeks, and 8 weeks after injection.

Interventions

DRUGLidocaine 3 cc

DRUGLidocaine 9 cc

9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide

DRUGTriamcinolone Acetonide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

1. participants with clinically diagnosed the rotator cuff impingement 2. participants aged 20 years and older 3. at least 1 month's duration 4. pain of moderate to severe intensity, defined as a score of 5 or more points on a 10-cm visual analog scale (VAS) rated from 0 (no pain) to 10 (worst imaginable pain)

Exclusion criteria

1. patients with adhesive capsulitis of the shoulder (normal radiograph of affected shoulder, and restriction of passive motion \>30° in ≥2 planes of movement) 2. previous trauma history at currently affected shoulder 3. previous corticosteroid injection history at the affected shoulder 4. abnormal calcification and/or primary osteoarthritis of the shoulder joint on plain radiographs 5. use of medication such as antiplatelet agent or anticoagulation.

Design outcomes

Primary

Measure	Time frame	Description
VAS	8 weeks	Visual analog score

Secondary

Measure	Time frame	Description
WORC	8 weeks	Western Ontario Rotator Cuff Index
Adverse reaction	8 weeks	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026